Today: 18 May 2026
Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps
18 May 2026
2 mins read

Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps

New York, May 18, 2026, 12:04 EDT

Ondas Inc. shares dropped roughly 10% in midday Nasdaq trade Monday, pulling back from last week’s gains as the company announced an all-stock deal to buy Israeli defense software firm Omnisys and filed for a resale of shares. The stock was last at $9.555, off an intraday low of $9.53, with volume topping 48 million.

Ondas wants to take its quick acquisitions in drone, counter-drone, and defense robotics and make one larger software platform for the battlefield. Now, traders are asking less about demand and more about whether Ondas can pull these deals together without flooding the market with extra shares.

Ondas said in a filing that on May 16 it struck a deal to buy all of Omnisys for $199 million in Ondas stock. The deal also includes up to $60 million more in stock-based earn-outs over three years if Omnisys hits certain milestones. An earn-out is extra payment tied to targets. Ondas expects the transaction to close in the second quarter, pending approvals and other conditions like the retention of all key employees and at least 90% of Omnisys staff and contingent workers.

Omnisys makes Battle Resource Optimization, or BRO, software for military planning and battlefield decisions. Ondas Chairman and CEO Eric Brock called it “a proven, battle-tested software platform.” Oshri Lugassy, co-CEO of Ondas Autonomous Systems, said the deal brings “true closed-loop operations.” Omnisys CEO Ofer Yarden described BRO as “a unique, battle-proven capability.” Ondas Inc.

CTech, the Israeli tech outlet, said Omnisys is based in Rosh Haayin and has about 185 staff. Omnisys would become a subsidiary of Ondas. CTech also called this Ondas’ 15th acquisition in two years. Earlier deals included Airobotics, Roboteam, and Sentrycs.

Ondas filed a prospectus supplement that morning tied to the possible resale of 2,264,491 shares from its Mistral deal. The company said any money would go to the selling shareholders, not to Ondas itself, and a daily cap on share sales is tied to average trading volume. A resale filing doesn’t require shares to hit the market right away, but it can weigh on the stock if investors think more supply is coming.

Ondas is feeling some heat after a big earnings-fueled rally. The company on May 14 posted first-quarter revenue of $50.1 million, more than ten times what it did a year ago, and lifted its 2026 revenue outlook to at least $390 million. The company also reported a $457 million pro forma backlog and had $1.48 billion in cash, cash equivalents, restricted cash and short-term investments at the end of March. Adjusted EBITDA came in at a loss of $10.9 million, which excludes interest, taxes, depreciation and some non-cash costs.

Ondas’s latest quarterly report points to why the stock is still exposed to dilution and execution worries. The company had 495.8 million common shares outstanding as of May 13. First-quarter operating cash outflow was $51.3 million. Three customers made up 32%, 20%, and 17% of revenue in the period, another sign the company’s results can be uneven.

Peer action pointed to Monday’s selling being tied mainly to the company itself. AeroVironment, a listed drone and defense group, gained roughly 1.5%. Kratos Defense picked up about 2.2%. Palantir, which works with Ondas, dipped 1.3%.

The risk is clear. Delays with Omnisys, tougher employee-retention terms, or customers holding off on orders could make it harder for Ondas to turn backlog into more consistent profit. Ondas has told investors to expect adjusted EBITDA losses to stay high in the second quarter and improve later in the year.

Right now, the stock isn’t moving much on talk of battlefield AI. Proof is what counts. Investors are eyeing whether Ondas can get operating leverage out of acquisitions, cash and backlog, and do it without more pressure on the shares.

Latest articles

Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps

Ondas Shares Drop Following $199 Million AI Defense Deal, Traders Eye Next Steps

18 May 2026
Ondas Inc. shares dropped about 10% to $9.555 in midday Nasdaq trading Monday after announcing a $199 million all-stock acquisition of Israeli defense software firm Omnisys and filing for potential resale of over 2.2 million shares tied to a previous deal. Trading volume topped 48 million shares. The Omnisys deal is expected to close in Q2, pending approvals and retention of key staff.
POET Gets $400M Infusion But Shares Drop

POET Gets $400M Infusion But Shares Drop

18 May 2026
POET Technologies closed a US$400 million direct investment with MMCAP International, issuing 19 million shares and warrants at $21 each. Shares fell 14.2% to $13.70 in heavy Nasdaq trading after opening higher. The funding follows a $50 million Lumilens order and a first-quarter net loss of $12.3 million. TSX Venture shares did not trade due to a Canadian holiday.
Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

18 May 2026
Plug Power shares dropped 9.8% to $3.41 in late-morning trading Monday, erasing part of last week’s post-earnings rally. The company reported first-quarter revenue of $163.5 million and improved margins, but posted a net loss of $245.3 million. Investors remain concerned about cash burn and future dilution. Other hydrogen stocks also fell sharply.
Ford’s Energy Bump Cools Off Despite EDF Tie-Up; EV Worries Still Linger

Ford’s Energy Bump Cools Off Despite EDF Tie-Up; EV Worries Still Linger

18 May 2026
Ford shares fell 1.2% to $13.24 by midday Monday after announcing a battery-storage deal with EDF and a new Europe product plan. The EDF agreement could bring up to 20 GWh of storage orders over five years, but deliveries start in 2028. Ford also plans to launch seven new models in Europe by 2029.

Popular

Sunshine Biopharma Up Premarket After Steep Fall; Traders Track $6M Filing

Sunshine Biopharma Up Premarket After Steep Fall; Traders Track $6M Filing

18 May 2026
Sunshine Biopharma shares jumped about 147% to $0.70 in premarket trading Monday after a steep drop Friday, following news of a $6 million share-and-warrant registration and a quarterly net loss of $1.24 million. The company reported first-quarter sales fell 9.1% to $8.1 million, citing the end of distribution deals in 2025.
POET Gets $400M Infusion But Shares Drop
Previous Story

POET Gets $400M Infusion But Shares Drop

Go toTop